Saturday 17 October 2026 Export SYRE’s income statement to Excel — free account

Spyre Therapeutics, Inc.

Spyre Therapeutics, Inc.’s revenue for fiscal 2023 (year ended December 2023) was $886,000.00, down 62.0% from fiscal 2022. In the quarter to June 2026, EPS grew 26.5% and free cash flow fell 50.1%, each against the same quarter a year earlier.

79.90 0.20 −0.25%

Follow SYRE

Alert me

Market cap: $7.4B
P/E: 0.0×
Fwd P/E: −4.8×
Dividend yield: —
F-score: 3/9
Altman Z: −3.82
Beneish M: n/a
Dividend safety: n/a

Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K

	Older periods	Sep '25	Dec '25	Mar '26	Jun '26
ROE Full definition →	+8 more TTM periods Free account	(63.28%)	(33.69%)	(42.63%)	(28.52%)
ROA Full definition →		(32.19%)	(22.39%)	(26.91%)	(20.90%)
ROIC Full definition →		0.00%	0.00%	0.00%	0.00%
Return on Tangible Assets Full definition →		(32.50%)	(21.58%)	(26.43%)	(16.12%)
Average Days of Receivables Full definition →		—	—	—	—
Free Cash Flow per Share Full definition →		(2.68)	(2.64)	(2.36)	(2.47)
Free Cash Flow Full definition →		(161.87)	(169.25)	(185.63)	(208.94)
Other line items
Cash ROIC Full definition →		(17.20%)	(11.50%)	(13.14%)	(9.30%)
Accounts Payable Turnover Full definition →		0.00	0.00	0.00	0.00
Average Days of Payables Full definition →		0.00	0.00	0.00	0.00
Tax Rate Full definition →		0.00	0.00	0.00	0.00
Research and Development Expense of Revenue Full definition →		0.00%	0.00%	0.00%	0.00%
Selling, General and Administrative Expense of Revenue Full definition →		0.00%	0.00%	0.00%	0.00%
Share Based Compensation of Revenue Full definition →		0.00%	0.00%	0.00%	0.00%
Operating CF/Net income Full definition →		1.09	1.09	1.03	1.17
Revenue per Share Full definition →		0.00	0.00	0.00	0.00
Operating CF per Share Full definition →		(2.68)	(2.64)	(2.36)	(2.47)
Capex per Share Full definition →		0.00	0.00	0.00	0.00

Show all line items

Columns are period end dates

Stockrow Weekly